2024
Trends and regional differences for fertility preservation procedures in women with breast cancer
Turan V, Bedoschi G, Lee D, Barbosa C, de Oliveira R, Sacinti K, Sonmezer M, Lambertini M, Massarotti C, Schaub A, Wang E, Gayete-Lafuente S, Dunlop C, Anderson R, Bang H, Oktay K. Trends and regional differences for fertility preservation procedures in women with breast cancer. Clinical Breast Cancer 2024 PMID: 39428290, DOI: 10.1016/j.clbc.2024.09.011.Peer-Reviewed Original ResearchWomen of reproductive ageFertility preservationBreast cancerTissue cryopreservationYoung womenReproductive ageOvarian tissue cryopreservationFertility preservation methodsNormal ovarian functionOvarian stimulation cyclesFertility preservation proceduresFertility preservation practicesDiagnosed breast cancerOocyte cryopreservationOvarian stimulationTertiary centerMulticenter studyOvarian functionStimulated cyclesParticipating centersRegional time trendsBreastCancerPreservation proceduresChemotherapyFemale Fertility Preservation for Oncological Reasons
Erden M, Oktay K. Female Fertility Preservation for Oncological Reasons. 2024 DOI: 10.1016/b978-0-443-21477-6.00277-7.Peer-Reviewed Original ResearchGonadotoxic chemotherapyPrimordial folliclesOvarian tissue cryopreservationFertility preservation techniquesFemale fertility preservationFertility preservation interventionFertility preservation optionsEnhanced DNA repairPelvic radiotherapyOvarian suppressionRadical surgeryOvarian insufficiencyTissue cryopreservationOncological reasonsOvarian damageFertility preservationPharmacological optionsPharmacological agentsPre-treatment preparationPreservation optionsCancer treatmentApoptotic deathBiological parenthoodChemotherapyDNA double-strand breaks
2022
Chapter 11 Preoperative Evaluation and Preparation for Ovarian Tissue Transplant Surgery
Oktay K, Turan V. Chapter 11 Preoperative Evaluation and Preparation for Ovarian Tissue Transplant Surgery. 2022, 109-115. DOI: 10.1016/b978-0-12-823344-3.00009-1.Peer-Reviewed Original ResearchPreoperative evaluationTransplantation surgeryFertility preservation methodsOvarian tissue cryopreservationOvarian autotransplantationOvarian stimulationHealthy babyTransplant surgeryPrepubertal girlsTissue cryopreservationSurgeryWomenPreparation of womenOnly optionAutotransplantationChemotherapyBabiesEvaluation
2020
Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer
Goldfarb S, Turan V, Bedoschi G, Taylan E, Abdo N, Cigler T, Bang H, Patil S, Dickler M, Oktay K. Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer. Breast Cancer Research And Treatment 2020, 185: 165-173. PMID: 32930927, PMCID: PMC7877450, DOI: 10.1007/s10549-020-05933-7.Peer-Reviewed Original ResearchConceptsAnti-Mullerian hormoneOvarian reserveAdjuvant chemotherapyBreast cancerAMH levelsChemotherapy regimensCompletion of ACSerum AMH levelsAdjuvant tamoxifenAMH recoveryChemotherapy groupPrimary diagnosisBaseline ageMethodsOne hundredAMH assessmentRegimensChemotherapyYoung womenTamoxifenSignificant recoveryCancerMixed effects modelsMonthsTreatment effectsWomenIMPACT OF ADJUVANT CHEMOTHERAPY OR TAMOXIFEN ALONE ON THE OVARIAN RESERVE OF YOUNG WOMEN WITH BREAST CANCER: A PROSPECTIVE LONGITUDINAL STUDY
Oktay K, Turan V, Bedoschi G, Taylan E, Bang H, Dickler M, Goldfarb S. IMPACT OF ADJUVANT CHEMOTHERAPY OR TAMOXIFEN ALONE ON THE OVARIAN RESERVE OF YOUNG WOMEN WITH BREAST CANCER: A PROSPECTIVE LONGITUDINAL STUDY. Fertility And Sterility 2020, 114: e531-e532. DOI: 10.1016/j.fertnstert.2020.09.051.Peer-Reviewed Original Research
2019
Ovarian Stimulation in Women with Breast Cancer
Turan V, Oktay K. Ovarian Stimulation in Women with Breast Cancer. 2019, 105-115. DOI: 10.1007/978-3-030-24086-8_10.Peer-Reviewed Original ResearchFertility preservation optionsOvarian stimulationBreast cancerPreservation optionsEffective fertility preservation optionsEstrogen-sensitive malignanciesReproductive-aged womenCommon cancer typesCytotoxic chemotherapyGonadal failureAged womenOocyte cryopreservationNumber of womenCancer typesCancerWomenStimulationTreatmentHigh levelsChemotherapyPatientsMalignancyOptionsRadiotherapyEstradiol
2015
Menstruation is an unreliable surrogate in the assessment of ovarian damage by chemotherapy: a prospective longitudinal study with AMH levels as the gold standard
Bedoschi G, Goldfarb S, Quistorff J, Goswami S, Moy F, Dickler M, Oktay K. Menstruation is an unreliable surrogate in the assessment of ovarian damage by chemotherapy: a prospective longitudinal study with AMH levels as the gold standard. Fertility And Sterility 2015, 104: e262-e263. DOI: 10.1016/j.fertnstert.2015.07.825.Peer-Reviewed Original ResearchChapter 4 The Current Understanding of Clinical Data on Ovarian Toxicity from Cancer Treatment
Turan V, Oktay K. Chapter 4 The Current Understanding of Clinical Data on Ovarian Toxicity from Cancer Treatment. 2015, 47-61. DOI: 10.1016/b978-0-12-801591-9.00004-7.Peer-Reviewed Original ResearchCancer treatmentComplications of chemotherapySystemic lupus erythematosusPremature ovarian insufficiencyQuality of lifeOvarian damageLupus erythematosusOvarian toxicityAutoimmune diseasesOvarian functionBRCA mutationsReproductive ageRelative riskChemotherapy agentsClinical dataOvarian insufficiencySurvival rateChemotherapeutic agentsOvarian cellsChemotherapyHuman dataTreatmentCurrent understandingErythematosusComplicationsOvarian Tissue Cryopreservation: Where Are We Now?
Bedoschi G, Oktay K. Ovarian Tissue Cryopreservation: Where Are We Now? 2015, 71-78. DOI: 10.1007/978-3-319-17849-3_6.Peer-Reviewed Original ResearchFertility preservationOvarian stimulationOvarian cortical piecesAdvanced treatment strategiesPre-pubertal childrenOvarian cryopreservationCortical piecesSurvival outcomesOvarian functionCancer careCancer patientsTreatment strategiesEndocrine functionOocyte cryopreservationAccelerated phaseEarly detectionCancer communityPatientsTransplantationFirst descriptionStimulationSufficient time periodChemotherapySuccessful restorationCancer
2014
A prospective longitudinal study of the impact of breast cancer chemotherapy on ovarian reserve: do individuals have differing susceptibilities?
Oktay K, Goldfarb S, Bedoschi G, Quistorff J, Grunblatt E, Cigler T, Moy F, Patil S, Goswami S, Dickler M. A prospective longitudinal study of the impact of breast cancer chemotherapy on ovarian reserve: do individuals have differing susceptibilities? Fertility And Sterility 2014, 102: e151. DOI: 10.1016/j.fertnstert.2014.07.517.Peer-Reviewed Original ResearchSphingosine-1-phosphate, a protector against chemotherapy-induced ovarian follicle apoptosis, does not diminish the effectiveness of chemotherapy
Titus S, Stobezki R, Turan V, Halicka D, De Sutter P, Oktay K. Sphingosine-1-phosphate, a protector against chemotherapy-induced ovarian follicle apoptosis, does not diminish the effectiveness of chemotherapy. Fertility And Sterility 2014, 102: e39. DOI: 10.1016/j.fertnstert.2014.07.139.Peer-Reviewed Original Research
2013
Fertility preservation in the female with cancer
Rodriguez-Wallberg K, Oktay K. Fertility preservation in the female with cancer. 2013, 273-281. DOI: 10.1017/cbo9780511997761.031.Peer-Reviewed Original ResearchFertility preservationMale cancer patientsFertility preservation strategiesImpact of cancerPost-treatment managementHormone therapySuch patientsCancer patientsNursing staffArtificial reproductive technologiesReproductive endocrinologyTesticular tissueReproductive medicineCancerReproductive technologiesPatientsMale fertilityCliniciansMenCryopreservation of spermChemotherapyPreservation strategiesSurgeryOncologistsTherapy
2012
Ovarian cryopreservation.
Jeong K, Aslan E, Ozkaya E, Sonmezer M, Oktay K. Ovarian cryopreservation. Minerva Medica 2012, 103: 37-46. PMID: 22278067.Peer-Reviewed Original ResearchConceptsFertility preservationOvarian tissueNon-malignant diseasesFuture autotransplantationOvarian cryopreservationOvarian failurePrepubertal girlsReproductive endocrinologistsMalignant cellsTeam approachWhole ovariesHeterotopic locationNew promising strategyAutotransplantationSignificant delayDiseaseTissue piecesTissuePromising strategySlow freezingChemotherapyLaparoscopyPatientsEndocrinologistsOncologists
2011
A multicenter analysis of the predictors of fertility preservation in women with breast cancer: Role of neoadjuvant chemotherapy.
Kim J, Oktay K, Gracia C, Lee S, Morse C, Mersereau J. A multicenter analysis of the predictors of fertility preservation in women with breast cancer: Role of neoadjuvant chemotherapy. Journal Of Clinical Oncology 2011, 29: 9118-9118. DOI: 10.1200/jco.2011.29.15_suppl.9118.Peer-Reviewed Original Research
2010
In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation
Oktay K, Buyuk E, Rodriguez-Wallberg K, Sahin G. In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation. Reproductive BioMedicine Online 2010, 20: 634-638. PMID: 20219430, DOI: 10.1016/j.rbmo.2010.01.012.Peer-Reviewed Original ResearchConceptsBreast cancer patientsMature oocyte yieldCancer patientsOvarian stimulationOocyte yieldFertility preservationFertility preservation cyclesMature oocytesCryopreservation cyclesTotal numberSecondary analysisVitro maturationImmature oocytesPatientsIVMEmbryo cryopreservationFertilization rateOocytesStimulationUseful strategyMaturationChemotherapy
2009
Recent Advances in Fertility Preservation for the Female
Oktem O, Oktay K. Recent Advances in Fertility Preservation for the Female. 2009, 95-102. DOI: 10.1007/978-1-60327-392-3_6.Peer-Reviewed Original Research
2007
Impact of previous chemotherapy on ovarian production of estradiol, progesterone, and AMH: an in vitro controlled study
Oktem O, Oktay K. Impact of previous chemotherapy on ovarian production of estradiol, progesterone, and AMH: an in vitro controlled study. Fertility And Sterility 2007, 88: s14. DOI: 10.1016/j.fertnstert.2007.07.066.Peer-Reviewed Original Research
2006
O-287 Ovarian reserve is impaired in cancer patients with normal baseline FSH who previously received chemotherapy as determined by response to controlled ovarian stimulation and anti-mullerian hormone measurements: A controlled study
Azim A, Rauch E, Ravich M, Witkin S, Oktay K. O-287 Ovarian reserve is impaired in cancer patients with normal baseline FSH who previously received chemotherapy as determined by response to controlled ovarian stimulation and anti-mullerian hormone measurements: A controlled study. Fertility And Sterility 2006, 86: s123-s124. DOI: 10.1016/j.fertnstert.2006.07.327.Peer-Reviewed Original ResearchO-227 Impact of breast cancer chemotherapy on ovarian reserve: A prospective analysis by menstrual history and ovarian reserve markers
Reh A, Oktem O, Lostritto K, Oktay K. O-227 Impact of breast cancer chemotherapy on ovarian reserve: A prospective analysis by menstrual history and ovarian reserve markers. Fertility And Sterility 2006, 86: s97-s98. DOI: 10.1016/j.fertnstert.2006.07.259.Peer-Reviewed Original ResearchO-229 In vitro maturation increases the number of oocytes and embryos cryopreserved from cancer patients undergoing controlled ovarian hyperstimulation (COH) prior to chemotherapy
Oktay K, Azim A, Sahin G, Yin H, Zaninovic N, Veeck-Gosden L. O-229 In vitro maturation increases the number of oocytes and embryos cryopreserved from cancer patients undergoing controlled ovarian hyperstimulation (COH) prior to chemotherapy. Fertility And Sterility 2006, 86: s98-s99. DOI: 10.1016/j.fertnstert.2006.07.261.Peer-Reviewed Original Research